The FDA underscored cases including two deaths and a suicide linked to patients taking semaglutide, which Novo markets as Ozempic and Wegovy. ...

Needham analyst Ryan MacDonald upgraded Hims & Hers (HIMS) to Buy from Hold with a $30 price target after the announcement that Novo Nordisk (NVO) has set aside its differences and will partner with the company once more, enabling Hims to sell commercially available doses of Ozempic and Wegovy, including the new pill form factor. The partnership alleviates concerns around legal risk, says the firm, which believes today’s move up in shares “still understates the revenue opportunity now ahead” given that the ...

Core Insights - Wall Street analysts are adjusting their ratings and price targets for several companies, including Novo Nordisk, Korn Ferry, Jefferies Financial Group, and Talkspace, reflecting concerns over pipeline performance, valuation compression, and acquisition outcomes [1][2]. Novo Nordisk (NVO) - TD Cowen downgraded Novo Nordisk from Buy to Hold, reducing the price target from $45 to $42, citing disappointing clinical data for CagriSema and lagging prescriptions for Ozempic [1]. - The stock is currently trading at $39.78, down 21.82% year-to-date and 53.14% over the past year, with a 52-week high of $80.53 [2]. - Despite strong Q4 2025 revenue of $45.32 billion, management has guided for a sales decline of 5% to 13% in 2026 due to pricing pressures and competition [1][2]. Korn Ferry (KFY) - Truist maintained a Buy rating on Korn Ferry but cut the price target from $88 to $75, attributing the reduction to lower industry multiples rather than fundamental concerns [1]. - The company reported Q3 FY2026 revenue of $725.04 million, up 7.2% year-over-year, and adjusted diluted EPS of $1.28, exceeding estimates [2]. - The stock is trading at $62.63, down 5.13% year-to-date, with a consensus price target of $79, indicating it is viewed as undervalued [1][2]. Jefferies Financial Group (JEF) - Morgan Stanley downgraded Jefferies from Overweight to Equal Weight, setting a price target of $49, reflecting concerns over credit and advisory softness [1]. - The stock is currently at $38.16, down 37.95% year-to-date, and has missed EPS estimates in its most recent quarter [2]. - Despite a strong FY2025 performance with investment banking net revenues up 20%, legal uncertainties related to First Brands litigation are impacting sentiment [1][2]. Talkspace (TALK) - KeyBanc downgraded Talkspace to Sector Weight from Buy following its acquisition by Universal Health Services for $5.25 per share, which removes investment upside and downside risk [1]. - The stock is trading at $5.12, reflecting a 41.05% increase year-to-date as the acquisition premium has been factored in [2]. - The company reported Q4 2025 revenue of $63.0 million, growing 29.3% year-over-year, and ended the year debt-free with approximately $93 million in cash and securities [2].

Novo Nordisk got a warning letter from the US Food and Drug Administration for not reporting all suspected side effects in patients who took its blockbuster Ozempic. https://t.co/lKuoummBrc ...

Novo Nordisk receives FDA warning regarding US inspection in 2025 | ReutersSkip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivThe logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, November 24, 2025. REUTERS/Tom Little Purchase Licensing Rights, opens new tab- CompaniesNovo Nordisk A/SFollowU.S. Food and Drug AdministrationFollowCOPENHAGEN, March 10 (Reuters) - ...

A seasoned consulting specialist at a leading Central Asian bank. The author behind Novo Capital brings half a decade of experience delivering strategic insight and analysis for the bank's clientele within the private banking branch. Launching the career back in 2020 after graduating from a top CA university, the author developed a resilient methodology forged amidst global market volatility, focusing on corporate valuation, due diligence for investment opportunities, and crafting spot-on forecasts that gui ...

记者丨韩利明 编辑丨季媛媛 骆一帆 随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。 业绩榜单中，强生以全球941.93亿美元的总营收斩获榜首，旗下创新制药和医疗科技两大核心 业务板块分别收入604.01亿美元（+6%）和337.92亿美元（+6.1%）；礼来凭借44%的高增 速，实现651.79亿美元的全年营收，成为增速最快的头部药企。此外，赛诺菲、诺华、阿斯利 康、艾伯维等头部企业营收均保持上升趋势，共同支撑全球制药行业稳步发展。 | | | | | 2025年营收前十跨国药企财务数据(单位:亿美元) | | | | --- | --- | --- | --- | --- | --- | --- | | 排名 | 公司 | 全球总营收 | 同比增速 | 中国区营收 | 同比增速 | 备注 | | 1 | 强生 | 941.93 | 6% | | | | | 2 | 罗氏 | 744. 28 | 7% | 36. 71 | 10% | 全球营收615. 16亿瑞士法郎:中国 区制药业务营收30.34亿瑞士法 郎,按1瑞士法郎=1. 2099美元换算 | | 3 | 礼来 | 6 ...

Group 1 - Novo Nordisk received a broker downgrade due to concerns over its duopoly status in diabetes and weight loss markets being threatened [1]

Don’t just invest—dominate with Tech Contrarians' realized return on closed positions of 65.8% since inception. You’ll get exclusive insights into high-focus stocks, curated watchlists, one-on-one portfolio consultations, and everything from live portfolio tracking to earnings updates on 50+ companies. Subscribe today.Hims & Hers ( HIMS ) shares surged as much as 55% in pre-market trading on Monday morning after news that the company is creeping back into bed with Novo Nordisk ( NVO ). The excitementTech St ...

Core Insights - Hims & Hers Health Inc. has formed a significant partnership with Novo Nordisk to offer weight-loss medications, marking a strategic shift and enhancing its healthcare solutions portfolio [1][3] - The collaboration resolves a previous legal dispute and positions Hims & Hers to capitalize on the growing demand for accessible and affordable weight loss treatments in the U.S. [1][3] Partnership Details - The partnership allows Hims & Hers to provide U.S. customers access to FDA-approved GLP-1 treatments, including semaglutide injections and tablets, which are expected to impact the U.S. weight loss market significantly [2] - Hims & Hers will continue to offer compounded semaglutide on a limited basis and will cease promoting compounded GLP-1s in its marketing materials [3] Stock Performance - Following the announcement of the partnership, HIMS stock increased to $21.95, reflecting a 39.45% rise, with daily fluctuations between $20.99 and $23.51 [2] - The company's market capitalization is approximately $4.82 billion, with a trading volume of 109.37 million shares [2] Future Prospects - CEO Andrew Dudum expressed enthusiasm about the partnership, emphasizing the evolving U.S. weight loss landscape with more affordable, FDA-approved medications and flexible dosing options [3] - The collaboration positions Hims & Hers to enhance its competitive edge against other telehealth companies like Teladoc Health and Amwell [1]